论文部分内容阅读
肿瘤内浸润淋巴细胞(TIL)和外周血淋巴细胞(PBL)在被rIL-2激活后,都具有杀伤肿瘤细胞的作用,而且均已用于肿瘤患者的过继免疫治疗,究竟两者有何差别,为此作者将它们作了如下比较。选择7例进展期上皮卵巢癌患者作为研究对象,用~(51)Cr 释放法检测PBL、TIL 在rIL-2激活后对K562、OV-2774、自身卵巢肿瘤细胞、同种异体卵巢肿瘤细胞的细胞毒作用,结果PBL、TIL 有相同强度的肿瘤杀伤作用和相同的靶细胞杀伤范围。用[~3H]dT 掺入法测PBL、TIL 在rIL-2作用下的
Both intratumoral infiltrating lymphocytes (TILs) and peripheral blood lymphocytes (PBLs) have the effect of killing tumor cells after being activated by rIL-2, and have been used in adoptive immunotherapy of tumor patients. What is the difference between the two? For this reason, the author made the following comparisons. Seven patients with advanced epithelial ovarian cancer were selected as the study subjects, and the (51)Cr release assay was used to detect the expression of PBL and TIL in patients with K562, OV-2774, autologous ovarian tumor cells, and allogeneic ovarian tumor cells after rIL-2 activation. As a result of cytotoxicity, PBL and TIL have the same intensity of tumor killing and the same target cell killing range. Using [~3H]dT incorporation method to measure PBL and TIL under the action of rIL-2